NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative drug-delivery platform DehydraTECH(TM) alters the way cannabinoids enter the bloodstream, which results in increased absorption. A recent article discussing LXRP reads, “Its proprietary technology promises multiple advantages in cannabinoid edibles. First, it masks the undesirable taste typically found in cannabinoid edibles, eliminating the need to add sweetening agents and enabling sugar-free options. Second, it increases the product’s absorption rate, with absorption occurring at two- to five-times higher rates than other edibles. Finally, it reduces the time of onset; effects of the product are felt within 15–20 minutes of consumption rather than the typical 60–120 minutes. In a March 2016 focus study, subjects ranked Lexaria’s formulation as the best tasting and most palatable option. They also found it to deliver the highest-quality THC experience overall.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer